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Background: CHFR expression has previously been established as a powerful predictor for
response to taxane based first-line chemotherapy in non-small cell lung cancer. It is currently
unknown however, if reduced CHFR expression correlates with certain molecular subtypes of
lung cancer.
Purpose: In order to determine which patients may benefit from CHFR biomarker testing we
conducted the present study to characterize clinical and molecular characteristics of patients
with reduced vs. high CHFR expression.
Approach: We utilized the extensive molecular and clinical data of the most recent adeno- and
squamous cell carcinoma datasets from The Cancer Genome Atlas (TCGA) project. CHFR
expression, analyzed by RNA-seq, was classified as high vs. low based on the median CHFR
expression level and correlated with the presence or absence of lung cancer specific mutations
(EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA for adenocarcinomas and
FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR for squamous cell carcinomas).
Results: Reduced CHFR expression was associated with EGFR exon19/21 mutations in adeno-
carcinoma OR 0.23 (95%CI: 0.06e0.88) and male gender in squamous cell carcinoma (OR
0.46 (95%CI 0.23e0.92), p Z 0.02).
Published by Elsevier Ltd.C, Winship Cancer Institute, Atlanta, GA 30322, USA. Tel.: þ1 404 778 4817; fax: þ1 404 778 5530.
mory.edu (J.C. Brandes).
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Fig. 1 CHFR expression z-scores for A) adenocarcinomas and
B) squamous cell carcinomas. Median CHFR expression was
chosen as cutoff between ‘high’ and ‘low’ expression. In the
adenocarcinoma cohort, significantly more EGFR exon19 and 21
mutations were found in CHFR low expressing tumors.
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Reduced expression or epigenetic silencing of the mitotic
checkpoint gene “checkpoint with fork-head and ringfinger
domains” (CHFR) has recently been identified as powerful
predictor for taxane sensitivity in gastric-, colon and lung
cancer [1e3]. Reduced CHFR expression in patients with
non-small lung cancer (NSCLC) who received first-line
chemotherapy with carboplatin and paclitaxel predicts
clinical benefit (81% vs. 48%, pZ 0.03) and overall survival
(HR Z 0.24; 95% CI, 0.1e0.58%; P Z 0.002) [3]. These are
important observations since it allows physicians to select
patients for microtubular-targeted therapy based on their
CHFR expression status, and furthermore, to target CHFR
pharmacologically to overcome taxane resistance in pa-
tients whose tumors display high CHFR expression. NSCLC
can be molecularly characterized by the presence of mu-
tations in oncogenes and tumor suppressor genes, which
frequently determine the therapeutic approach to these
tumors. Targeted therapies for tumors with EGFR mutations
[4e6] and Alk-translocations [7] are available and new
targets such as RET and ROS1 fusions, BRAF, and ERBB2, are
rapidly emerging. Nonetheless, a large percentage of lung
cancers are not driven by single oncogene mutations and
improvements in better selection of standard chemo-
therapy drugs or the development of novel targeted ap-
proaches to overcome chemo-resistance are essential for
patients with these tumors. To find the most appropriate
place for CHFR testing in the ever more complex algorithms
for biomarker analysis in NSCLC, it is important to deter-
mine if reduced expression of CHFR is tied exclusively to
certain molecularly defined subtypes of NSCLC or,
conversely, if CHFR expression is independent from the
presence of lung cancer specific mutations. We therefore
analyzed CHFR expression and frequent relevant mutations
in NSCLC reported in The Cancer Genome Atlas (TCGA) for
both adenocarcinoma (EGFR, KRAS, ALK, MET, ERBB2, TP53,
STK11, ROS1, RET, NF1, Pik3CA) and squamous cell carci-
noma (FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR).
Materials and methods
Data acquisition
TCGA gene expression and mutation data for lung adeno-
[8] and squamous cell carcinomas [9] were obtained from
the cBioPortal for Cancer Genomics (www.cbioportal.org).
Clinical data were obtained directly from the TCGA data
portal (www.tcga-data.nci.nih.gov). For adenocarcinoma
(AC), the provisional dataset of 554 total tumors was used
(on 12/5/13). 294 of these were sequenced for mutations
and 129 of these also had available RNA-seq data for CHFR
mRNA expression (z-score). Mutation data were obtained
for (EGFR, KRAS, ALK, AKT, MET, ERBB2, TP53, STK11, ROS1,
RET, BRAF, PiK3CA). For squamous cell lung cancer (SCC),
data were obtained from the provisional dataset of 489
samples (on 12/5/13) of which 230 were sequenced for
mutations. Mutation data were obtained for (FGFR1,
FGFR2, FGFR3, STK11 and TP53). 178 of these samples had
available CHFR expression data by RNA-seq. For correlation
of CHFR expression with clinical characteristics, factorssuch as age, gender, race, smoking history and tumor stage
were considered.
Statistical analysis
Previous studies have shown that the percentage of tumors
with reduced CHFR expression is approximately 40% (95%CI
26e54%) [3]. In order to determine the best cutoff for
‘high’ vs. ‘low’ CHFR levels, we analyzed the distribution of
CHFR expression among adeno- and squamous cell lung
cancers. Given the known frequencies of reduced CHFR
expression, and given the fact that the inflection point of
the expression curves correlated with the median of CHFR
expression (Fig. 1A and B), we chose this value as cutoff to
classify CHFR expression as ‘high’ vs. ‘low’. SAS9.2 software
was used to determine the odds ratios that a mutation is
present in tumors with ‘high’ vs. ‘low’ CHFR expression.
Chi-square tests were used to determine statistical signifi-
cance. In addition, t-tests were used to compare CHFR
expression z-scores as continuous variables in relationship
to mutation data.Results
Correlation between CHFR expression and clinical
characteristics
The final cohort existed of 129 patients with AC and 180
patients with SCC. Clinical characteristics by CHFR
expression are listed in Table 1. For patients with squamous
cell carcinoma there was a statistically significant
Table 1 Clinical characteristics of patients with adeno- and squamous cell carcinoma based on CHFR expression status.
Adenocarcinoma Squamous cell carcinoma
CHFR low CHFR high p-value CHFR low CHFR high p-value
N 64 65 89 89
age median 64.4 65.8 0.82 68.1 67.2 0.45
gender M 23 (36%) 32 (49%) 0.13 72 (80%) 59 (66%) 0.02
W 41 (64%) 33 (51%) 17 (20%) 30 (34%)
Race White 45 (70%) 41 (63%) 0.66 53 (59%) 58 (65%) 0.48
African American 2 (3%) 2 (3%) 6 (7%) 3 (3%)
other or unknown 17 (27%) 22 (34%) 30 (34%) 28 (32%)
Smoking current 5 (8%) 15 (23%) 0.13 15 (18%) 13 (15%) 0.39
former 41 (64%) 39 (60%) 66 (74%) 73 (82%)
never 13 (20%) 7 (11%) 4 (4%) 2 (2%)
unknown 5 (8%) 4 (6%) 4 (4%) 1 (1%)
Stage I 34 (53%) 32 (49%) 0.41 48 (55%) 49 (55%) 0.37
II 16 (25%) 11 (17%) 19 (22%) 20 (22.5%)
III 12 (19%) 20 (31%) 18 (20%) 20 (22.5%)
IV 2 (3%) 2 (3%) 3 (3%) 0
missing 0 0 1 0
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expression (OR 0.46 (95%CI 0.23e0.92), pZ 0.02). No other
significant correlations between CHFR expression and age,
race, smoking status or disease stage at diagnosis were
found for either AC or SCC (Table 1).
Correlation between CHFR expression status and
lung cancer mutations
In AC, we determined the odds ratio for high vs. low CHFR
expression for 12 commonly mutated genes: EGFR, KRAS,
ALK, AKT, MET, ERBB2, TP53, STK11, ROS1, RET, BRAF,
PiK3CA. EGFR mutations were associated with a trend to-
wards decreased odds for ‘high’ CHFR expression (OR: 0.52
(95% CI: 0.19e1.42)). When only EGFR mutations in exon19
and exon21 which are associated with sensitivity to the
EGFR tyrosine kinase inhibitors erlotinib and gefitinib [4e6]
were considered, this correlation reached statistical sig-
nificance (OR 0.23 (95%CI: 0.06e0.88)) (Figs. 1A and 2).
Mean CHFR expression (by z-score) was 435.5 (95%CI
370.1e500.8) for tumors with EGFR (exon19/21) mutations
vs. 549 (95%CI 516.8e577.2) for all other adenocarcinomas
(Table2A)There was no significant correlation between
CHFR expression and any other mutation in AC. Squamous
cell carcinomas usually have a higher frequency of muta-
tions than adenocarcinomas however, driver mutations are
less well defined. Mutations in FGFR1-3 and occasionally in
EGFR or k-ras have been described for squamous cell car-
cinomas, and are potential targets for molecularly directed
therapy [9]. In addition, mutations in p53 are common in
SCC, occurring in more than 50% of cases. In the TCGA
cohort of patients with SCC, we did not find a correlation
between any of the mutations tested and CHFR expression
(Fig. 2B).
Discussion
CHFR expression is a novel biomarker to predict sensitivity
to taxane based chemotherapy in NSCLC. We havepreviously shown that, although CHFR is a frequent target
for aberrant promoter hypermethylation in other cancers,
such as colon-, gastric- and esophageal cancer [1], epige-
netic silencing in NSCLC is much less frequent [3]. The
clinical utility of CHFR expression could be through
personalization of chemotherapy treatments by selecting
patients with CHFR ‘low’ expression to microtubular-
targeted therapy while choosing alternative agents such
as pemetrexed or gemcitabine for patients with high CHFR
expression. In addition, CHFR may be an attractive target
for pharmacologic inhibition in an effort to overcome tax-
ane resistance in patients with ‘high’ CHFR expression.
The analysis of the TCGA cohorts indicates that pa-
tients with an EGFR mutation in exon19 and exon21 are
significantly more likely to have reduced levels of CHFR
mRNA expression. These findings suggest that constitutive
activation of the EGF receptor may be one of the up-
stream molecular events leading ultimately to decreased
CHFR expression. It is well recognized that oncogenic
driver mutations such as EGFR mutations but also ROS1
and Alk-translocations are more commonly found in
never-smokers. Our data demonstrate however, that in 14
out of 20 never smoking patients without associated EGFR
mutation no correlation with reduced CHFR expression
was observed. This suggests that a specific mechanistic
relationship may exist between constitutive EGFR acti-
vation and suppression of CHFR expression that is inde-
pendent from the effects of cigarette smoke. This is
further supported by the results of the IRESSA Pan-Asia
Study (IPASS) study, in which never or light former
smokers with EGFR mutations compared to those without
had significantly superior response rates not only when
they were treated with gefitinib but also following
chemotherapy with carboplatin and paclitaxel (47.3% vs.
23.5%) [10]. Other explanations for this observation are
possible such as differences in the frequency of p53 mu-
tations. However, the TCGA data show that this is less
likely: In the analyzed cohort there was no association
between EGFR mutations and p53 mutations (OR 1.16; 95%
CI 0.39e3.55). Reduced CHFR expression levels favoring
Fig. 2 Odds ratios (OR) and 95% Confidence intervals for the odds of high CHFR expression are shown for adenocarcinoma (A) and
squamous cell carcinoma specific mutations in lung cancer.
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tions are an attractive and plausible explanation.
Even though reduced CHFR expression is associated with
exon19 and 21 mutations in EGFR, it is important to
recognize however, that the majority of patients with low
CHFR expression do not have defined molecular charac-
teristics. Therefore analysis of CHFR expression should not
be restricted to certain molecular subtypes of NSCLC.
Several potential limitations of this study have to be
considered: In our previous report we studied CHFR protein
expression instead of CHFR mRNA levels as predictor for
taxane response [3]. While the median mRNA expression in
tumors with reduced CHFR protein expression in our orig-
inal cohort is lower than in tumors with high CHFR protein
expression, this correlation is not linear (data not shown).
Since no protein expression data for CHFR are available in
TCGA, a correlation between reduced CHFR protein
expression and EGFR exon19/21 mutations was not possible
in this study and will need to be confirmed in an indepen-
dent cohort. We have previously established that CHFR
promoter methylation in lung cancer is an infrequent event
and does not explain all instances of reduced CHFR protein
expression. In this TCGA dataset of sequenced adenocar-
cinomas who were also analyzed for promoter methylationon the Infinium 450 K human methylation array, none of the
tumors exceeded a threshold of a methylation beta-value
of 0.1 (at the CHFR locus), confirming our previous obser-
vation (data not shown), that CHFR expression in lung
cancer is rarely mediated by epigenetic events.
The relationship between reduced CHFR expression and
male gender in patients with squamous cell carcinomas is
interesting and deserves further explanation. A previous
study reported that CHFR expression is particularly
impaired in smoking related squamous cell carcinoma of
the lung [11]. Even though data about past, present or
never smoking status are available in TCGA, detailed in-
formation about the cumulative amount of cigarettes
smoked is not. It is therefore possible that the gender
specific differences are at least in part due to differences in
smoking patterns.
In summary, our report uses a cohort with unrivaled gene
expression and genomic data to characterize lung cancers
with ‘reduced’ vs. ‘high’ CHFR expression. Our data show
that reduced CHFR expression is not dependent on a
particular molecular subtype of lung cancer. The associa-
tions with EGFR (exon19/21) mutations in AC and with male
gender in SCC further suggest that CHFR expression is likely
regulated by different molecular mechanisms. Correlation
Table 2 CHFR expression (z-score) according to mutation
status.
A AC p-value
Mean (95%CI)
Mutationþ Mutation
EGFR 490.8 (401.8e571.7) 544.6 (512.1e577.2) 0.21
EGFR
exon
19/21
435.5(370.1e500.8) 549 (516.8e577.2) 0.02
KRAS 544.4 (488.4e600.4) 533.8 (498.8e569.9) 0.76
TP53 569.5 (524.2e614.8) 544.4 (468.5e547.8) 0.76
STK11 514.2 (401.9e626.4) 540.1 (509.2e571.0) 0.56
RET 559.7 (390.9e728.5) 535.2 (504.4e565.9) 0.69
ROS1 571.2 (342.0e800.5) 535 (504.6e565.4) 0.61
Alk 602 (489.3e714.6) 528.1 (497.2e559) 0.11
NRAS 632.4 () 535.9 (505.8e566.1) 0.56
BRAF 573.3 (467.0e679.7) 532.6 (501.0e564.2) 0.42
NF1 561.5 (464.1e658.8) 533.2 (501.3e565.1) 0.54
ERBB2 556.8 (414.6e699) 535.9 (505e566.8) 0.79
PIK3CA 652.7 (488.7e816.7) 532 (501.4e562.6) 0.12
B SCC
Mean (95%CI) p-value
Mutationþ Mutation
FGFR1 703.5 () 585 (548.5e621.5) 0.63
FGFR2 539.2 (37e1116.1) 586.7 (550.3e623.2) 0.7
FGFR3 716.0 (563.5e869.9) 582.7 (545.6e619.7) 0.28
FGFR1-3 636.3 (446.1e826.6) 583 (545.6e620.3) 0.52
TP53 583 (539.9e624.0) 596 (532.4e659.7) 0.77
STK11 909.6 (171.3e1647.8) 580.1 (544.0e616.2) 0.19
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and 21 may help explain differential sensitivity to taxanes
in this particular molecular lung cancer subtype.
Impact statement
CHFR is a novel biomarker for taxane sensitivity in NSCLC.
We utilized data from The Cancer Genome Atlas Project to
determine for the first time clinical and molecular char-
acteristics associated with reduced CHFR expression in
NSCLC. EGFR (exon19/2) mutations correlated with
reduced CHFR expression. However, reduced CHFR
expression was not limited to EGFR mutations and CHFR
expression testing should not be restricted to molecularly
defined subtypes of NSCLC.
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